NASDAQ:AQST Aquestive Therapeutics (AQST) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free AQST Stock Alerts $3.90 -0.38 (-8.88%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$3.90▼$4.2850-Day Range$2.51▼$6.0952-Week Range$1.15▼$6.23Volume2.12 million shsAverage Volume2.59 million shsMarket Capitalization$285.87 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Aquestive Therapeutics alerts: Email Address Aquestive Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside105.1% Upside$8.00 Price TargetShort InterestHealthy3.10% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$429,750 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.36) to ($0.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.73 out of 5 starsMedical Sector443rd out of 907 stocksPharmaceutical Preparations Industry200th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingAquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAquestive Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.10% of the outstanding shares of Aquestive Therapeutics have been sold short.Short Interest Ratio / Days to CoverAquestive Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aquestive Therapeutics has recently decreased by 2.16%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAquestive Therapeutics does not currently pay a dividend.Dividend GrowthAquestive Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AQST. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 23 people have searched for AQST on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.MarketBeat Follows22 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 10% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aquestive Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $429,750.00 in company stock.Percentage Held by InsidersOnly 8.39% of the stock of Aquestive Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 32.45% of the stock of Aquestive Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aquestive Therapeutics are expected to grow in the coming year, from ($0.36) to ($0.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aquestive Therapeutics is -27.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aquestive Therapeutics is -27.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Aquestive Therapeutics Stock (NASDAQ:AQST)Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Read More AQST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AQST Stock News HeadlinesApril 17, 2024 | investorplace.comComing FDA Approvals Could Send These 3 Drug Stocks SoaringApril 12, 2024 | globenewswire.comAquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of NeurologyApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 11, 2024 | msn.comPiper starts Aquestive at overweight, cites allergy reaction treatmentApril 11, 2024 | msn.comAquestive Therapeutics a new overweight at Piper on oral film productsMarch 25, 2024 | globenewswire.comAquestive Therapeutics Announces Closing of Underwritten Public Offering of Common StockMarch 20, 2024 | msn.comAquestive Therapeutics slumps 13%, prices $75M offeringMarch 20, 2024 | investorplace.comWhy Is Aquestive Therapeutics (AQST) Stock Down 14% Today?April 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 19, 2024 | globenewswire.comAquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common StockMarch 19, 2024 | finance.yahoo.comInsider Sell: Chief Innovation/Tech Officer Alexander Schobel Sells 50,000 Shares of Aquestive ...March 19, 2024 | globenewswire.comAquestive Therapeutics Announces Proposed Public Offering of Common StockMarch 15, 2024 | msn.com5 Growth Stocks Under $50 for March 2024March 15, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Allogene Therapeutics (ALLO), Aquestive Therapeutics (AQST) and Allakos (ALLK)March 14, 2024 | globenewswire.comAquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA MeetingMarch 12, 2024 | finance.yahoo.comInsider Sell: Chief Innovation/Tech Officer Alexander Schobel Sells 25,000 Shares of Aquestive ...March 11, 2024 | realmoney.thestreet.comAquestive Therapeutics price target raised by $1 at H.C. Wainwright, here's whyMarch 8, 2024 | seekingalpha.comAquestive Therapeutics, Inc. (AQST) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comAquestive Therapeutics Inc Reports Full Year 2023 Financial ResultsMarch 7, 2024 | realmoney.thestreet.comAquestive Therapeutics price target raised by $5 at Lake Street, here's whyMarch 7, 2024 | insidermonkey.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comAquestive Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 7, 2024 | finance.yahoo.comQ4 2023 Aquestive Therapeutics Inc Earnings CallMarch 6, 2024 | finanznachrichten.deAquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateMarch 6, 2024 | markets.businessinsider.comReiterating Outperform Rating on Aquestive: Buy Recommendation Amid Promising Anaphylm Developments and Strategic Market PositioningMarch 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Aquestive Therapeutics Amid Strong Pipeline and Market PotentialMarch 5, 2024 | investorplace.comAQST Stock Earnings: Aquestive Therapeutics Misses EPS, Beats Revenue for Q4 2023See More Headlines Receive AQST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today4/24/2024Next Earnings (Estimated)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AQST CUSIPN/A CIK1398733 Webwww.aquestive.com Phone(908) 941-1900FaxN/AEmployees135Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+105.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,870,000.00 Net Margins-15.56% Pretax Margin-15.07% Return on EquityN/A Return on Assets-13.39% Debt Debt-to-Equity RatioN/A Current Ratio2.24 Quick Ratio1.87 Sales & Book Value Annual Sales$50.58 million Price / Sales5.65 Cash FlowN/A Price / Cash FlowN/A Book Value($1.59) per share Price / Book-2.45Miscellaneous Outstanding Shares73,300,000Free Float67,151,000Market Cap$285.87 million OptionableOptionable Beta2.87 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Daniel Barber (Age 48)CEO, President & Director Comp: $925.35kMr. Alexander Mark Schobel (Age 65)Chief Innovation & Technology Officer Comp: $672.69kMs. Lori J. Braender BSBA (Age 68)Esq., J.D., Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $678.76kMr. A. Ernest Toth Jr. (Age 65)Chief Financial Officer Comp: $679.9kMs. Cassie Jung (Age 45)Senior Vice President of Operations Mr. Peter E. Boyd (Age 58)Senior Vice President of IT, HR & Communications Dr. Gary H. Slatko M.D. (Age 66)MBA, Chief Medical Officer Dr. Stephen Wargacki (Age 46)Senior VP of Research & Development Dr. Carl N. Kraus M.D. (Age 54)Chief Medical Officer Mr. Robert Charles ArnoldVP of Finance, Controller & Assistant SecretaryMore ExecutivesKey CompetitorsAtea PharmaceuticalsNASDAQ:AVIRVentyx BiosciencesNASDAQ:VTYXSilverback TherapeuticsNASDAQ:SBTXXOMANASDAQ:XOMATerns PharmaceuticalsNASDAQ:TERNView All CompetitorsInsiders & InstitutionsPFG Investments LLCBought 48,000 shares on 4/22/2024Ownership: 0.065%Alexander Mark SchobelSold 50,000 sharesTotal: $300,000.00 ($6.00/share)Alexander Mark SchobelSold 25,000 sharesTotal: $129,750.00 ($5.19/share)Armistice Capital LLCSold 876,000 shares on 2/13/2024Ownership: 5.877%Essex Investment Management Co. LLCBought 846,167 shares on 2/8/2024Ownership: 1.267%View All Insider TransactionsView All Institutional Transactions AQST Stock Analysis - Frequently Asked Questions Should I buy or sell Aquestive Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AQST shares. View AQST analyst ratings or view top-rated stocks. What is Aquestive Therapeutics' stock price target for 2024? 5 analysts have issued 1-year price objectives for Aquestive Therapeutics' shares. Their AQST share price targets range from $4.00 to $10.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 105.1% from the stock's current price. View analysts price targets for AQST or view top-rated stocks among Wall Street analysts. How have AQST shares performed in 2024? Aquestive Therapeutics' stock was trading at $2.02 at the start of the year. Since then, AQST shares have increased by 93.1% and is now trading at $3.90. View the best growth stocks for 2024 here. When is Aquestive Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our AQST earnings forecast. How were Aquestive Therapeutics' earnings last quarter? Aquestive Therapeutics, Inc. (NASDAQ:AQST) posted its quarterly earnings results on Tuesday, March, 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.04. The company had revenue of $13.21 million for the quarter, compared to analyst estimates of $11.79 million. What guidance has Aquestive Therapeutics issued on next quarter's earnings? Aquestive Therapeutics updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $48.0 million-$51.0 million, compared to the consensus revenue estimate of $48.1 million. What other stocks do shareholders of Aquestive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Organigram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB). When did Aquestive Therapeutics IPO? Aquestive Therapeutics (AQST) raised $60 million in an IPO on Wednesday, July 25th 2018. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers. Who are Aquestive Therapeutics' major shareholders? Aquestive Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include PFG Investments LLC (0.07%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, Lori J Braender and Peter E Boyd. View institutional ownership trends. How do I buy shares of Aquestive Therapeutics? Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AQST) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPrepare for a recession unlike any otherAmerican Hartford Gold GroupWill this $2 AI stock double overnight?Behind the MarketsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
